TY  - JOUR
A1  - Schmidbauer, Moritz L.
A1  - Ferse, Caroline
A1  - Salih, Farid
A1  - Klingner, Carsten
A1  - Musleh, Rita
A1  - Kunst, Stefan
A1  - Wittstock, Matthias
A1  - Neumann, Bernhard
A1  - Schebesch, Karl-Michael
A1  - Bösel, Julian
A1  - Godau, Jana
A1  - Lochner, Piergiorgio
A1  - Adam, Elisabeth H.
A1  - Jahnke, Kolja
A1  - Knier, Benjamin
A1  - Schirotzek, Ingo
A1  - Müllges, Wolfgang
A1  - Notz, Quirin
A1  - Dengl, Markus
A1  - Güldner, Andreas
A1  - Onur, Oezguer A.
A1  - Garcia Borrega, Jorge
A1  - Dimitriadis, Konstantinos
A1  - Günther, Albrecht
T1  - COVID-19 and intracranial hemorrhage: a multicenter case series, systematic review and pooled analysis
JF  - Journal of Clinical Medicine
N2  - Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
KW  - COVID-19
KW  - intracranial hemorrhage
KW  - prognosis
KW  - anticoagulation
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-255236
SN  - 2077-0383
VL  - 11
IS  - 3
ER  -